Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from...

Area of Science:

• Laboratory Medicine
• Clinical Chemistry
• Diabetology

Background:

• Hemoglobin A1c (HbA1c) measurement is crucial for diabetes management and therapy decisions.
• Current German guidelines (Rili-BAEK) allow wide deviations (±18% external, ±10% internal quality control), potentially masking imprecise results.
• The introduction of unprocessed fresh EDTA blood for HbA1c testing necessitates stricter quality control.

Purpose of the Study:

• To advocate for narrower acceptance limits for HbA1c internal (±3%) and external (±8%) quality controls in Germany.
• To address the inadequacy of current broad deviation limits in ensuring accurate HbA1c measurements for patient care.
• To highlight the need for improved quality assurance, especially for point-of-care testing (POCT) devices.

Main Methods:

• Analysis of the current Rili-BAEK guidelines for HbA1c external quality assessment (EQA).
• Evaluation of the impact of new EQA materials and unprocessed fresh EDTA blood on measurement accuracy.
• Review of the necessity for stricter quality control criteria in laboratory medicine.

Main Results:

• Existing broad deviation limits in EQA are insufficient for reliable HbA1c patient care.
• New, narrower acceptance criteria (±3% internal, ±8% external) are proposed for German EQA schemes.
• Stricter controls are essential to identify imprecisely measured HbA1c results and incorrectly calibrated devices.

Conclusions:

• Implementing tighter quality control limits for HbA1c measurements is vital for accurate diabetes diagnosis and treatment.
• Improved HbA1c measurement quality will prevent misdiagnosis and inappropriate patient management.
• Harmonizing quality standards will enhance patient safety and therapeutic efficacy in diabetes care.